PMID- 31732618
OWN - NLM
STAT- MEDLINE
DCOM- 20200508
LR  - 20200508
IS  - 1472-4146 (Electronic)
IS  - 0021-9746 (Linking)
VI  - 73
IP  - 5
DP  - 2020 May
TI  - The differences of clinicopathologic characteristics among subgroups of 
      reclassified HER2 fluorescence in situ hybridization (FISH) according to the 
      ASCO/CAP 2018 breast cancer HER2 testing guidelines.
PG  - 283-290
LID - 10.1136/jclinpath-2019-206222 [doi]
AB  - AIMS: The aim of this study is to analyse differences in clinicopathologic 
      features among reclassified human epidermal growth factor receptor-2 (HER2) 
      fluorescence in situ hybridization (FISH) results in breast cancers according to 
      2018 guidelines. METHODS: According to different ratios of HER2 copy numbers to 
      chromosome 17 centromere numbers (HER2/CEP17) and average HER2 copy numbers, 3795 
      invasive breast cancers were classified into six groups. Clinicopathologic 
      features were collected and compared among different FISH groups. RESULTS: There 
      were no statistically significant differences about HER2 positive rate between 
      2013 and 2018 guidelines (p=0.518). After re-evaluating these cases according to 
      2018 guidelines, the cases that converted to a HER2 positive status had 
      clinicopathologic features similar to samples in group 1 (ratio >/=2.0, HER2 >/=4.0). 
      Compared with group 5 (ratio <2.0, HER2 <4.0), the cases in groups 1 had higher 
      histological grade, more frequent occurrence of negative oestrogen receptor and 
      progesterone receptor status and a higher Ki67 index. The samples in group 4 
      (ratio <2.0, 4.0</=HER2<6.0) showed a higher histological grade and higher Ki67 
      index than did the samples in group 5 but had a lower histological grade and 
      lower Ki67 index than did the samples in group 1a (ratio >/=2.0, HER2 >/=6.0). 
      CONCLUSION: Different categories of HER2 FISH test results have significant 
      differences in clinicopathologic features. With no equivocal cases in 2018 HER2 
      guidelines, the clear division of HER2 status is helpful for making treatment 
      recommendations about HER2 targeted therapy.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Yang, Libo
AU  - Yang L
AD  - Department of Pathology, West China Hospital of Sichuan University, Chengdu, 
      Sichuan, China.
AD  - Laboratory of Pathology, West China Hospital of Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Chen, Min
AU  - Chen M
AD  - Department of Pathology, West China Hospital of Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Pu, Tianjie
AU  - Pu T
AD  - Department of Pathology, West China Hospital of Sichuan University, Chengdu, 
      Sichuan, China.
AD  - Laboratory of Pathology, West China Hospital of Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Wu, Shuang
AU  - Wu S
AD  - Department of Pathology, West China Hospital of Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Wei, Bing
AU  - Wei B
AD  - Department of Pathology, West China Hospital of Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Yang, Jieliang
AU  - Yang J
AD  - Department of Pathology, West China Hospital of Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Bu, Hong
AU  - Bu H
AD  - Department of Pathology, West China Hospital of Sichuan University, Chengdu, 
      Sichuan, China.
AD  - Laboratory of Pathology, West China Hospital of Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Zhang, Zhang
AU  - Zhang Z
AUID- ORCID: 0000-0002-4822-4471
AD  - Department of Pathology, West China Hospital of Sichuan University, Chengdu, 
      Sichuan, China zhangzhang714@163.com.
LA  - eng
PT  - Journal Article
DEP - 20191115
PL  - England
TA  - J Clin Pathol
JT  - Journal of clinical pathology
JID - 0376601
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/classification/*diagnosis/metabolism/pathology
MH  - Female
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Practice Guidelines as Topic
MH  - Receptor, ErbB-2/*metabolism
MH  - Retrospective Studies
OTO - NOTNLM
OT  - breast cancer
OT  - immunohistochemistry
COIS- Competing interests: None declared.
EDAT- 2019/11/17 06:00
MHDA- 2020/05/10 06:00
CRDT- 2019/11/17 06:00
PHST- 2019/09/18 00:00 [received]
PHST- 2019/10/21 00:00 [revised]
PHST- 2019/10/22 00:00 [accepted]
PHST- 2019/11/17 06:00 [pubmed]
PHST- 2020/05/10 06:00 [medline]
PHST- 2019/11/17 06:00 [entrez]
AID - jclinpath-2019-206222 [pii]
AID - 10.1136/jclinpath-2019-206222 [doi]
PST - ppublish
SO  - J Clin Pathol. 2020 May;73(5):283-290. doi: 10.1136/jclinpath-2019-206222. Epub 
      2019 Nov 15.